Interleukin‐33 regulates tissue remodelling and inhibits angiogenesis in the eye. Issue 1 (16th November 2016)

• Record Type: Journal Article
• Authors: Theodoropoulou, Sofia; Copland, David A; Liu, Jian; Wu, Jiahui; Gardner, Peter J; Ozaki, Ema; Doyle, Sarah L; Campbell, Matthew; Dick, Andrew D
• Is Part Of: Journal of pathology. Volume 241:Issue 1(2017)
• Page Start: 45
• Page End: 56
• Publication Date: 2016-11-16
• Subjects: IL‐33 -- AMD -- RPE -- angiogenesis -- wound healing; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.4816
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: Age‐related macular degeneration (AMD) is the leading cause of central vision loss worldwide. Loss of retinal pigment epithelium (RPE) is a major pathological hallmark in AMD with or without pathological neovascularization. Although activation of the immune system is implicated in disease progression, pathological pathways remain diverse and unclear. Here, we report an unexpected protective role of a pro‐inflammatory cytokine, interleukin‐33 (IL‐33), in ocular angiogenesis. IL‐33 and its receptor (ST2) are expressed constitutively in human and murine retina and choroid. When RPE was activated, IL‐33 expression was markedly elevated in vitro . We found that IL‐33 regulated tissue remodelling by attenuating wound‐healing responses, including reduction in the migration of choroidal fibroblasts and retinal microvascular endothelial cells, and inhibition of collagen gel contraction. In vivo, local administration of recombinant IL‐33 inhibited murine choroidal neovascularization (CNV) formation, a surrogate of human neovascular AMD, and this effect was ST2‐dependent. Collectively, these data demonstrate IL‐33 as a potential immunotherapy and distinguishes pathways for subverting AMD pathology. © 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.